Charles Schwab Investment Management Inc Cabaletta Bio, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 109,260 shares of CABA stock, worth $240,372. This represents 0.0% of its overall portfolio holdings.
Number of Shares
109,260
Previous 125,845
13.18%
Holding current value
$240,372
Previous $593,000
59.53%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CABA
# of Institutions
115Shares Held
39.6MCall Options Held
297KPut Options Held
98.6K-
Black Rock Inc. New York, NY4.76MShares$10.5 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.07MShares$8.96 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.63MShares$8 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.87MShares$6.31 Million0.0% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.76MShares$6.07 Million1.64% of portfolio
About Cabaletta Bio, Inc.
- Ticker CABA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,014,000
- Market Cap $63.8M
- Description
- Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...